Stock Analysis
Fate Therapeutics, Inc. (FATE) Stock Analysis
Fate Therapeutics, Inc. (FATE) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Fate Therapeutics, Inc. (FATE) currently has an AIQ Score of 34/100, indicating a bearish setup. Momentum is the strongest factor at 47/100. Quality is the weakest current factor at 23/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
FATE at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $2.31 |
| AIQ Score | 34/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $283.24M |
| P/E Ratio | -2.23 |
| Forward P/E | — |
| EPS | -$0.25 |
| Revenue TTM | $2.08M |
| Dividend Yield | 0.00% |
| Beta | 2.55 |
| Volume | 742.39K |
| 52-week range | $0.94-$3.23 |
| RSI 14 | 48.72 |
| 50-Day SMA | $2.62 |
| 200-Day SMA | $1.75 |
| Analyst Price Target | $5.62 |
| Next Earnings | Nov 12, 2026 |
Create a free account to keep researching stocks
You have viewed 2 stock pages in the last 24 hours. Create a free account to keep researching current evidence.
FATE
OverviewFATE Stock Analysis Summary
Fate Therapeutics, Inc. (FATE) currently has an AIQ Score of 34/100, indicating a bearish setup. Momentum is the strongest factor at 47/100. Quality is the weakest current factor at 23/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, FATE has AIQ Score of 34/100 with Momentum base of 47/100 and fading Quality at 23/100. Wait for component alignment before adding exposure.
Momentum (47/100) leads while Quality (23/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.86% stock move · FATE classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is FATE Bullish or Bearish Right Now?
FATE currently has a bearish overall setup. Momentum is the strongest factor at 47/100, while Quality is weakest at 23/100. The current evidence suggests a defensive setup.
- - Analyst target implies +143.29% upside from the latest quote.
- - Value is the current constraint at 34/100.
- - Risk Resilience is weak at 34/100.
- - Technical consensus has more sell votes than buy votes (34 vs 6).
Current Consensus
FATE's Technical Analysis Consensus is currently Strong Sell, with 6 buy, 5 neutral, and 34 sell votes. FATE's 14-day RSI is 48.72, which places the stock in a neutral momentum range. FATE's beta is 2.55, indicating greater market sensitivity than the broad market.
What Changed in FATE?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the FATE Outlook?
The current bearish outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
FATE Decision Framework
Public evidence layers, setup checks, and risk context for Fate Therapeutics, Inc..
Fate Therapeutics, Inc. (FATE) Stock Analysis
Fate Therapeutics, Inc. has an AIQ Score of 34/100 in a Defensive regime. Momentum is strongest at 47/100. Beta is 2.55, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | FATE is in a Defensive AIQ regime with score 34/100. |
| Signal Conflict | The primary conflict is that momentum leads at 47/100 while quality lags at 23/100. |
| Factor Evidence | Momentum 47/100 · Value 34/100 · Quality 23/100 · Risk 34/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 47/100.
Momentum is 47/100 and RSI (14) is 48.7.
FATE is in a Defensive regime at 34/100.
Risk factor is 34/100 with beta 2.55 and annual volatility 96.18%.
Current conflict: momentum leads at 47/100 while quality lags at 23/100.
FATE Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
FATE Fundamentals
FATE valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
FATE Technical Analysis
FATE technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
FATE Stock Catalysts
Track FATE earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
FATE Dividend Analysis
FATE dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
FATE Financial Data
FATE revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
FATE Risk Analysis
FATE volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
FATE Stock News
FATE stock news, market tone, recent headlines, and catalyst context.
FATE vs Gene Editing / Genomics / Biotech Peers
Current peer cohort: FATE · FOLD · IBRX · ICLR · IONS. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| FATE Current stock | 34/100 | 34/100 | 47/100 | 34/100 | 1.29 | 96.18% | Current |
| FOLD Amicus Therapeutics | 41/100 | 35/100 | — | 66/100 | 2.61 | 44.15% | FATE vs FOLD |
| IBRX ImmunityBio | 60/100 | 34/100 | 63/100 | 28/100 | 1.53 | 104.47% | FATE vs IBRX |
| ICLR ICON | 53/100 | 67/100 | 58/100 | 48/100 | 0.35 | 67.35% | FATE vs ICLR |
| IONS Ionis Pharmaceuticals | 32/100 | 34/100 | 25/100 | 41/100 | -0.3 | 40.02% | FATE vs IONS |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 11, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Sep 12, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching FATE
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for FATE
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
FATE Stock FAQ
What is FATE stock price today?
Fate Therapeutics, Inc.'s current stock price is $2.31. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is FATE bullish or bearish right now?
FATE's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is FATE's market cap?
FATE's market cap is $283.24M based on the latest completed market-close snapshot from Sep 11, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is FATE's current P/E ratio?
FATE's current P/E ratio is -2.23 based on the latest completed market-close snapshot from Sep 11, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is FATE's RSI?
FATE's 14-day RSI is 48.72 based on the latest completed market-close snapshot from Sep 11, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is FATE above its 50-day and 200-day moving averages?
FATE is -11.80% from its 50-day SMA and 31.83% from its 200-day SMA based on the latest completed market-close snapshot from Sep 11, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is FATE's next earnings date?
FATE's next earnings date is currently listed as Nov 12, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does FATE pay a dividend?
FATE's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 11, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.